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Abstract 
Background: It is unknown whether canagliflozin, a selective sodium glucose co‑transporter 2 inhibitor, reduces 
epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary 
artery disease.
Methods and results: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes 
mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) 
area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Cana‑
gliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and 
decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT 
area. No association was found between any of these changes.
Conclusion: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect 
on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in 
these patients (UMIN000021327).
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Background
Epicardial adipose tissue (EAT) is associated with various 
cardiovascular risk factors such as body mass index and 
area of visceral adipose tissue, as well as with the sever-
ity of coronary artery disease (CAD) [1–4]. Insulin resist-
ance is closely associated with the physiology of adipose 
tissue [5–7]. In addition, it has been reported that various 
interventions that improve insulin resistance such as diet 
therapy and exercise also reduce EAT, which implies that 
insulin resistance is a potential target in reducing EAT 
and preventing CAD [8].
Selective sodium glucose co-transporter 2 (SGLT2) 
inhibitors improve glucose metabolism by inhibiting 
SGLT2 in the early proximal tubule, which leads to 
increased urinary glucose excretion by the kidneys, 
and thus reduce the plasma glucose levels in an insulin-
independent manner. Selective sodium glucose co-trans-
porter 2 inhibitors also reduce weight and the amount 
of visceral adipose tissue (VAT) by caloric elimination, 
and improve insulin resistance [9–11]. Therefore, SGLT2 
inhibitors might be capable of reducing EAT.
Previous pilot studies show that the SGLT2 inhibitors 
luseogliflozin and ipragliflozin reduce the EAT volume, 
based on magnetic resonance imaging evaluation [12, 13]. 
However, it has not been elucidated whether the SGLT2 
inhibitor canagliflozin reduces EAT thickness in patients 
with type 2 diabetes or whether the change in EAT thick-
ness through canagliflozin treatment can be detected 
with echocardiography. The aim of this study was to clar-
ify whether canagliflozin reduces EAT thickness, based 
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on echocardiography evaluation, in patients with type 2 
diabetes.
Methods
We enrolled 15 patients with type 2 diabetes mellitus 
and treated them with 100 mg canagliflozin once a day, 
as a monotherapy or as add-on/combination therapy 
with existing antidiabetic treatment between May 2016 
and December 2016. One meta-analysis showed that 
the adverse effects of canagliflozin were not influenced 
by its dosage [14]; however, the effect of canagliflozin on 
glycated hemoglobin (HbA1c) is dose-dependent [10]. 
Thus, we fixed the dosage of canagliflozin at 100  mg to 
exclude the dosage effects of canagliflozin. During the 
study period, the patients did not alter their use of anti-
diabetic drugs such as dipeptidyl peptidase-4 inhibitors, 
α-glucosidase inhibitors, sulfonylureas, biguanides, glin-
ides, thiazolidinediones, and insulin, or other drugs that 
can affect glucose metabolism such as angiotensin-con-
verting enzyme inhibitors/angiotensin II receptor block-
ers, statins, diuretics, or β-blockers.
Clinical measurements were performed before ini-
tiating the treatment and at 3 and 6  months after ini-
tiating treatment. Epicardial adipose tissue thickness 
was evaluated with echocardiography [15]. Echocardi-
ography was performed using commercially available 
ultrasound machines (Vivid E9, GE Healthcare, Mil-
waukee, WI, USA or Aplio 500, Toshiba Medical Sys-
tems, Tochigi, Japan) with a sector transducer. A 
high-frequency linear probe (7.5–11  MHz) was used 
to measure the EAT thickness at the end of systole in 
the anterior interventricular groove. While assess-
ing EAT thickness, the distal portion of the left ante-
rior descending coronary artery was identified and the 
probe was carefully rotated until a longitudinal sec-
tion of the artery was obtained. The EAT thickness was 
measured as the distance between the outer wall of the 
myocardium and the visceral layer of the epicardium, 
perpendicular to the pericardium. Measurements were 
performed during three cardiac cycles for each param-
eter, and the mean for each parameter was used for 
statistical analysis. Interobserver and intraobserver 
variability were 1.1  ±  1.1 and 0.5  ±  0.5  mm, respec-
tively [15]. All measurements were obtained by a single 
sonographer who was blinded to the metabolic status 
of the study participants. A representative echocardio-
graphic image is shown in Fig. 1.
The areas of VAT and subcutaneous adipose tissue 
(SAT) at the level of the umbilicus were measured using 
the bioelectrical impedance method with a fat area ana-
lyzer (Dual Scan HDS-2000®; Omron, Japan). Previous 
studies have shown a strong correlation between the 
Fig. 1 A representative echocardiographic image of epicardial fat tissue. a Measurement of epicardial fat thickness using a high‑frequency linear 
probe. b Schematic illustration of the echocardiographic image. EAT epicardial fat tissue, LAD left anterior descending coronary artery, LV left ventri‑
cle, RV right ventricle
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visceral fat area measured with the fat area analyzer and 
the visceral fat area measured with computed tomogra-
phy [16, 17].
Whole body skeletal muscle mass was measured using 
multifrequency bioelectrical impedance method with a 
body composition analyzer (Inbody720; Biospace, Seoul, 
Korea) [18].
The glucose-lowering efficacy of SGLT2 inhibitors 
was assessed by measuring the HbA1c level before ini-
tiating therapy and at 3 and 6  months after initiating 
therapy, in addition to assessment by using other labo-
ratory data.
The exclusion criteria included active malignancy 
and current therapy with drugs that affect glucose 
metabolism, if they were to be altered during the study 
period.
Informed consent was obtained from all individuals 
before enrollment. This study was carried out in conform-
ance with the declaration of Helsinki and the study pro-
tocol was approved by the Tokushima University Hospital 
Ethics Committee (Tokushima, Japan; Approval Number, 
2549). In accordance with the Japanese governmental eth-
ical guidelines and the Study Protocol (UMIN000021327), 
monitoring was performed by members of the Clinical 
Trial Center for Developmental Therapeutics, Tokushima 
University Hospital (Tokushima, Japan).
Statistical analysis
For continuous variables, the average was estimated and 
each value was expressed as the mean  ±  the standard 
deviation and categorical parameters were expressed in 
percentages. Clinical data before initiating therapy with 
canagliflozin and at 3 months and at 6 months after initi-
ating it were compared using the paired t-test. All statisti-
cal analyses were performed using JMP software (version 
11; SAS Institute, Cary, NC, USA). Statistical significance 
was defined as P < 0.05.
Results
Clinical characteristics of study patients
Characteristics of the patients enrolled in this study are 
shown in Table  1. Overall, these patients had moderate 
diabetes, an HbA1c level of 7.1 ± 0.5%, and a body mass 
index of 27 ± 5 kg/m2.
Over the 6-month period, none of them experienced 
severe side effects such as hypoglycemic episodes, which 
would have resulted in a hospital visit or hospitalization. 
However, two patients were excluded from the analysis 
because one patient stopped taking canagliflozin owing 
to generalized fatigue and the other patient was found 
to have stage IV gastric cancer and discontinued this 
therapy.
Effects of SGLT2 inhibitors on blood glucose and HbA1c 
levels
At 6  months of therapy, canagliflozin had significantly 
decreased the HbA1c level from 7.1 ± 0.5% to 6.7 ± 0.6% 
(P < 0.05) (Fig. 2).
Effect of SGLT2 inhibitors on EAT, VAT, SAT, and skeletal 
muscle weight
Canagliflozin significantly decreased the EAT thickness 
from 9.3 ± 2.5 to 8.1 ± 2.3 mm at 3 months (P < 0.01) and 
to 7.3 ± 2.0 mm at 6 months (P < 0.001) (Fig. 2). The VAT 
significantly decreased from 109  ±  44 to 97  ±  46  cm2 
at 3 months of therapy (P < 0.05), but was not different 
at 6 months of therapy. The SAT significantly decreased 
from 193 ± 71 to 177 ± 81 cm2 at 3 months of therapy 
(P < 0.05), but was not different at 6 months of therapy 
(Table 2). Canagliflozin therapy did not affect the skeletal 
muscle weight (Table 2).
The change in EAT thickness at 6 months was not asso-
ciated with a change in HbA1c, which indicated that the 
effect of canagliflozin on reducing EAT is independent of 
its glucose-lowering effect (Additional file  1: Figure S1). 
Table 1 Clinical characteristics of patients
PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, 
DPP-4 dipeptidyl peptidase-4
Unless indicated otherwise, data are presented as mean ± standard deviation
Variables
Number of patients 13
Male, n (%) 5 (38%)
Age, years 62 ± 12
Body mass index, kg/m2 27 ± 5
Coronary risk factors
 Dyslipidemia, n (%) 7 (54%)
 Hypertension, n (%) 8 (62%)
 Current sumoker/past smoker 0/3 (23%)
Coronary artery disease 4 (31%)
 History of old myocardial infarction 0 (0%)
 History of PCI 3 (23%)
 History of CABG 1 (8%)
Anti‑diabetic drugs
 DPP‑4 inhibitors 5 (38%)
 α‑Glucosidase inhibitors 1 (8%)
 Sulfonylureas 1 (8%)
 Biguanides 1 (8%)
 Glinides 1 (8%)
 Thizoladinediones 0 (0%)
 Insulin 2 (15%)
Statins 7 (54%)
Antihyperuricemics 3 (23%)
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In addition, the change in EAT thickness was not associ-
ated with the change in the surface area of VAT or SAT 
or the change in body weight at 6  months (Additional 
file 1: Figure S2).
Effect of SGLT2 inhibitors on laboratory data
There was a significant increase in the hematocrit 
from 42 ± 5% to 43 ± 5% at 3 months (P < 0.05) and to 
45 ± 6% at 6 months (P < 0.01). There was also a signifi-
cant decrease in the serum uric acid level from 4.9 ± 1.3 
to 4.2  ±  1.1  mg/dL at 3  months (P  <  0.01), and to 
4.2 ± 1.0 mg/dL (P < 0.01) at 6 months of therapy with 
canagliflozin. However, no effects were observed on the 
levels of low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides, 
serum creatinine, estimated glomerular filtration rate, 
and urinary albumin (Table 2).
Discussion
We demonstrated that canagliflozin reduces EAT at 3 and 
6 months without affecting VAT, SAT, and muscle weight. 
Epicardial adipose tissue, a lipid storage depot, covers the 
surface of the heart and surrounds the coronary arteries 
while also functioning as an endocrine organ secreting 
hormones and inflammatory cytokines [19]. Epicardial 
adipose tissue releases proinflammatory and proathero-
genic cytokines, including tumor necrosis factor-α, 
monocyte chemoattractant protein-1, interleukin-6, 
nerve growth factor, resistin, visfatin, omentin, leptin, 
plasminogen activator inhibitor-1, and angiotensinogen 
[19]. These cytokines influence coronary atherogenesis 
and myocardial function because there is no fibrous fas-
cial layer to impede the diffusion of free fatty acids and 
adipokines between EAT and the underlying vessel wall, 
as well as the myocardium [19]. Thus, reducing EAT can 
help in preventing CAD.
It has been reported that weight loss [20], bariatric sur-
gery [8], exercise [21], or atorvastatin therapy [22, 23] 
lead to a regression of EAT. A meta-analysis has shown 
that exercise has little effect on reducing EAT and body 
weight [8]. On the contrary, diet therapy reduces EAT 
and body weight, which indicates that caloric elimina-
tion has more preferable effects, compared to caloric 
consumption. Therefore, SGLT2 inhibitors can be good 
candidates to reduce EAT effectively. Recent studies have 
shown that luseogliflozin and ipragliflozin treatment for 
12 weeks reduced EAT volume, which was evaluated by 
magnetic resonance imaging evaluation [12, 13].
It has been reported that canagliflozin reduces VAT 
in 52 weeks [10]. However, the effect of canagliflozin on 
EAT has not been investigated. In our study, canagliflozin 
treatment demonstrated a tendency to reduce VAT, but 
it was not statistically significant in 6 months because of 
the heterogeneity of the participants. However, canagli-
flozin treatment reduced EAT by 3  months, which was 
earlier than we expected. Precise mechanisms underlying 
these results are unknown. However, EAT has a higher 
rate of fatty acid intake and secretin than VAT, and func-
tions as a local energy source during times of energy 
demand. The high metabolic turnover might explain why 
EAT was more sensitive to SGLT2 treatment, compared 
to VAT [24].
Table 2 The effects of canagliflozin on anthropometric and laboratory data
eGFR estimated glomerular filtration rate, LDL low-density lipoprotein, HDL high-density lipoprotein, VAT visceral adipose tissue, SAT  subcutaneous adipose tissue
Data are presented as mean ± standard deviation. * P < 0.05 vs before treatment, ** P < 0.01 vs before treatment
Variables Before treatment 3 month after treatment 6 month after treatment
Body weight, kg 69 ± 13 69 ± 13 67 ± 11*
VAT area,  cm2 109 ± 44 97 ± 46* 101 ± 47
SAT area,  cm2 193 ± 71 177 ± 81* 182 ± 82
Skeletal muscle weight, kg/m2 15 ± 2 15 ± 2 15 ± 2
Systolic blood pressure, mmHg 131 ± 16 131 ± 20 125 ± 22
Diastolic blood pressure, mmHg 73 ± 11 77 ± 10 72 ± 8
Heart rate, b.p.m 75 ± 11 76 ± 11 76 ± 17
Hematocrit, % 42 ± 5 43 ± 5* 45 ± 6**
Serum creatinine, mg/dL 0.8 ± 0.3 0.9 ± 0.3 0.9 ± 0.3
eGFR, ml/min./1.73 m2 65 ± 19 63 ± 20 62 ± 18
Urinary albumin, mg/g ceratinine 37 ± 54 26 ± 27 33 ± 32
LDL‑choresterol, mg/dL 106 ± 36 114 ± 42 119 ± 44
HDL‑cholesterol, mg/dL 58 ± 21 58 ± 19 60 ± 20
Triglyceride, mg/dL 189 ± 100 160 ± 88 170 ± 121
Uric acid, mg/dL 4.9 ± 1.3 4.2 ± 1.1** 4.2 ± 1.0**
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Epicardial adipose tissue has been evaluated with mag-
netic resonance imaging or computed tomography (CT) 
to quantify its thickness and volume [25, 26]. Magnetic 
resonance imaging and CT are superior to echocardi-
ography for measuring overall EAT volume. Echocar-
diography is advantageous because it is noninvasive, 
costs less, does not expose the patient to radiation, and 
is easier to perform, although it provides only measure-
ments of the regional thickness of EAT. Recent evidence 
has shown that echocardiographic epicardial fat thick-
ness reflects visceral adiposity rather than general obe-
sity, which is correlated with metabolic syndrome, insulin 
resistance, CAD, and subclinical atherosclerosis. Thus 
EAT evaluation with echocardiography is a simple tool 
for estimating cardiometabolic risk [27–29]. We previ-
ously demonstrated that the reliability of our method of 
evaluating EAT thickness in the anterior interventricu-
lar groove to predict the presence of CAD is similar to 
that of CT scan [15]. A meta-analysis demonstrated that 
EAT thickness in the anterior interventricular groove is 
associated with CAD [30]. In addition, we used a linear 
probe with high frequency (7.5–11 MHz) with high spe-
cial resolution of 0.1–0.2 mm, which is used clinically to 
measure the intima-media thickness of the carotid artery. 
The sector probe that is used for usual cardiac scanning 
is a lower frequency probe (2–3 MHz) with a low special 
resolution of 0.5 mm, which might be insufficient to eval-
uate EAT thickness. Thus, by using this noninvasive and 
highly sensitive method, we monitored EAT periodically 
during the therapy and detected the fine change in EAT 
thickness after canagliflozin treatment.
We showed that canagliflozin decreased the level of 
uric acid. The mechanism by which SGLT2 inhibitors 
reduce the level of uric acid has not been fully estab-
lished. However, the facilitative glucose transporter 9 iso-
form 2 (SLC2A9b) may be involved: it is expressed at the 
apical membrane of the renal tubular cells and exchanges 
glucose for uric acid [31]. Higher glucose concentrations 
in urine, which are attributable to canagliflozin treat-
ment, could increase the exchange of uric acid in the api-
cal membrane of tubular cells through the transporter, 
increase the release of uric acid from blood into the 
urine, and thereby reduce the serum uric acid levels. This 
potential mechanism has been supported by the evidence 
of trans-stimulation of uric acid efflux with high glucose 
concentrations in Xenopus oocytes expressing SLC2A9b 
[32].
The present study had several limitations. First, the 
study is a single-arm observational study with a small 
sample size. Thus, the study contains a patient selection 
bias and less statistical power due to the patients’ hetero-
geneity. Second, the observational period was relatively 
short. Hence, the long-term effects of SGLT2 inhibi-
tors could not be analyzed. Third, we could not exclude 
the effects of concomitant drugs that can affect glucose 
metabolism, even though the patients’ drugs were not 
changed during the study period. Fourth, because of a 
methodological issue, we evaluated only EAT thickness 
and did not study the effect of canagliflozin on EAT vol-
ume. Randomized, large, clinical cohort studies with a 
longer observation period are needed to evaluate further 
the findings of this study.
Conclusion
Canagliflozin treatment for 6 months reduced EAT thick-
ness, as evaluated by echocardiography, in patients with 
type 2 diabetes mellitus, independent of its effect on low-
ering blood glucose, which suggests that canagliflozin 
may have an effect in preventing cardiovascular events in 
these patients.
Fig. 2 The effects of canagliflozin on the glycated hemoglobin 
(HbA1c) level and epicardial fat thickness. Values before initiat‑
ing therapy and after 3 or 6 months are compared. a Canagliflozin 
decreased the HbA1c level at 6 months of therapy. b Canagliflozin 
decreased the epicardial fat tissue thickness at 3 and 6 months of 
therapy. *P < 0.05, **P < 0.01, and ***P < 0.001, compared to values 
before initiating therapy
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